Non-Randomized, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Peginterferon Alfa-2a and Copegus Combination Therapy After Single and Multiple Doses in Patients With Chronic Hepatitis C and Moderate Renal Impairment, Severe Renal Impairment, or End-Stage Renal Disease Undergoing Hemodialysis
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C; Renal failure; Renal impairment
- Focus Pharmacokinetics
- Sponsors Roche
- 18 Jun 2008 Status changed from in progress to completed according to Roche.
- 20 Jun 2006 New trial record.